In the year 2020, an estimate of 2.2 million people has been diagnosed with lung cancer. It is the second most commonly diagnosed cancer and is among leading cause of cancer deaths. NSCLC is the most common type of lung cancer, accounting for about 84% of all lung cancer diagnoses. The lung cancer drug, sugemalimab, has shown positive results following a phase 3 trial.
The GEMSTONE-302 study has evaluated the efficacy of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-time treatment for stage 4 NSCLC versus using chemotherapy alone for such patients. The results from two phase III trials have shown that sugemalimab has significantly prolonged progression-free survival in NSCLC patients. In this trial, they have found that use of sugemalimab after chemotherapy in patients with locally advanced, unresectable stage III NSCLC resulted in significantly longer progression-free survival. The results from the study were published in The Lancet Oncology.
The analysis from Gemstone-32 has shown that at a median follow-up of 17.8 months, sugemalimab with chemotherapy improved progression-free survival in comparison with placebo with chemotherapy in patients with previously untreated squamous and non-squamous metastatic non-small cell lung cancer, irrespective of PD-L1 expression levels.
“We are highly encouraged to see that sugemalimab in combination with chemotherapy demonstrates significant clinical benefit, including improvement in both PFS and OS, when compared to placebo plus chemotherapy across a broad spectrum of patients with stage IV NSCLC in this phase 3 study,” Vince Miller, MD, physician-in-chief at EQRx, stated in a press release. “Price remains a barrier to accessing innovative therapies for many people with lung cancer around the world, despite the availability of multiple anti-PD-(L)1 therapies,” he added.
The detailed results of the GEMSTONE-302 study will be presented at a future medical congress.
The information shared in this blog is for educational purposes only. Please consult your medical practitioner for any health issues.
Subscribe to our newsletter or follow us on Twitter or Facebook today and never miss an update!